The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.83% and ...

Discover the first FDA-approved weight loss medication for obstructive sleep apnea, Zepbound by Eli Lilly. Learn how it can reduce apnea events and CPAP market.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

European markets edge higher as Novo Nordisk rebounds, with gains led by healthcare and tech sectors despite lingering ...

Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug ...

The drug helped patients reduce their weight by only 22.7 per cent, falling short of the anticipated result. Novo’s shares ...

Asian and European stock markets were largely getting off to a good start to a holiday-shortened Christmas week. Bargain hunting was in evidence as Novo Nordisk rose following a sharp drop for the ...

Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...